Synagis News
Most Popular Synagis Story
Motavizumab failure shifts spotlight to RSV vaccines
The news this week that AstraZeneca ($AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street Read more...
Latest Headlines
- December 23, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
